Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
ACADIA Pharmaceuticals (ACAD) Stock Price & Analysis
2,156 Followers
ACAD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.17 - $33.99
Previous Close$15.21
Volume5.28M
Average Volume (3M)1.90M
Market Cap
$2.83B
Enterprise Value$2.19B
Total Cash (Recent Filing)$366.69M
Total Debt (Recent Filing)$48.10M
Price to Earnings (P/E)-968.8
Beta0.48
Next Earnings
Jul 31, 2024EPS Estimate
$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding164,771,521
10 Day Avg. Volume1,584,840
30 Day Avg. Volume1,903,309
Standard Deviation0.15
R-Squared0.02
Alpha0.00083
Financial Highlights & Ratios
Price to Book (P/B)7.76
Price to Sales (P/S)5.46
Price to Cash Flow (P/CF)8.30
P/FCF Ratio8.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.47
Enterprise Value/Gross Profit4.33
Enterprise Value/Ebitda-15.82
Forecast
1Y Price Target
$29.11Price Target Upside91.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
ACADIA Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Drug EfficacyACP-101 showed nominal efficacy in a previous trial with tolerable side effects, which makes it an interesting candidate for further development.
Financial PerformanceACAD maintained its sales outlook ranges for both Nuplazid and Daybue, indicating stable future revenue expectations.
Market PotentialThe Daybue opportunity is underappreciated in the long term, suggesting potential for future growth as the market recognizes its value.
Bears Say
Clinical Trial SetbacksEarlier Phase 3 trial testing intranasal carbetocin was inconclusive and had to be prematurely stopped, impacting the trial's power.
Financial Forecast AdjustmentsAnalyst has lowered Daybue sales estimate for the year, citing the higher than expected number of patients discontinuing the drug versus new additions.
Sales Performance ConcernsDaybue sales came in below consensus and at the low end of management's guidance, signaling potential difficulties in achieving future sales targets.
---
Ownership Overview
51.63% Insiders
19.06% Mutual Funds
20.61% Other Institutional Investors
8.70% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACAD FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was $15.17 and its highest was $33.99 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
Currently, no data Available
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is Jul 31, 2024 which is in 82 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on May 08, 2024. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of $0.049 by $0.051.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is $0.19.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 165,203,490 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of $0.1 in its last earnings report, beating expectations of $0.049. Following the earnings report the stock price went down -11.208%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Among the largest hedge funds holding ACADIA Pharmaceuticals’s share is Baker Bros Advisors LP. It holds ACADIA Pharmaceuticals’s shares valued at 1B.
---
ACADIA Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.11 (91.39% Upside)
$29.11 (91.39% Upside)
Blogger Sentiment
Bullish
ACAD Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 860.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.51%
12-Months-Change
Fundamentals
Return on Equity
-14.73%
Trailing 12-Months
Asset Growth
27.41%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
---
ACAD Company Deck
---
ACAD Earnings Call
Q1 2024
0:00 / 0:00
---
ACAD Stock 12 Month Forecast
Average Price Target
$29.11
▲(91.39% Upside)
Technical Analysis
Best Analysts Covering ACAD
1 Year
1 Year Success Rate
14/24 ratings generated profit
1 Year Average Return
+8.13%
reiterated a buy rating 2 months ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +8.13% per trade.
---